Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential ...

These findings will fuel future work to develop nanoparticles containing therapeutic mRNA and siRNA as researchers study their effects in clinically translatable animal models. "We can use our ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Both STP705 and STP707 are made of two siRNA oligonucleotides that hit transforming growth factor beta 1 (TGF-β1) and cyclooxygenase 2 (COX-2) mRNA, gatekeeper targets for oncology and fibrosis.

Problem: siRNA might depress mRNA levels but not induce the expected phenotype. Controls: Looking for a decrease in levels of your targeted mRNA isn't enough, Rozenfeld says; you should also look for ...

Even though the delivered siRNA was designed for possessing full sequence complementarity to the bacterial mRNA, downregulation of the target protein was achieved at the translational level rather ...

Technically demanding protocols and reagents for cloning and propagating adenoviral and other recombinant viral systems, advances in gene suppression technology with sh- or siRNA, and capabilities for ...

National Institutes of Health officials have urged scientists to remove all references to mRNA vaccine technology from their ...

A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...